Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis

Artificial Organs

Volumn 31, Issue 3, 2007, Pages 200-207

  Opatrný Jr , Karel ^a   Richtrová, Pavlína ^a   Polanská, Kamila ^a   Wirth, Jan ^a   Šefrna, František ^a   Brandl, Martin ^b   Falkenhagen, Dieter ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Activated clotting time; Citrate; Complement; Hemodialysis; Hemostasis; Ionized calcium; Leukocytes; Thrombogenicity

Indexed keywords

CALCIUM; CHEMICAL ACTIVATION; GLYCOPROTEINS; HEMODIALYZERS; IONIZATION;

ACTIVATED CLOTTING TIME; ANTI-COAGULATION; CITRATE; COMPLEMENT; COMPLEMENT ACTIVATIONS; HAEMODIALYSIS; HAEMOSTASIS; IONIZED CALCIUM; LEUCOCYTES; THROMBOGENICITY;

DIALYSIS;

ACID CITRATE DEXTROSE; BIOLOGICAL MARKER; CALCIUM CHLORIDE; CALCIUM ION; CITRATE TRISODIUM; COMPLEMENT; COMPLEMENT COMPONENT C5A; HEPARIN; POLYSULFONE; RECOMBINANT ERYTHROPOIETIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; DIALYSIS EQUIPMENT AND SUPPLIES; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOGENICITY; TREATMENT DURATION;

EID: 33847673290     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2007.00365.x     Document Type: Article

References (37)

1. Morita Y, Johnson RW, Dorn RE, Hall DS. Regional anticoagulation during hemodialysis using citrate. Am J Med Sci 1961;242:32-43.
2. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C; ADQI Workgroup. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002;62:1855-63.
3. The EBPG Expert Group on Hemodialysis. European best practice guidelines for hemodialysis (Part 1). Section V. Chronic intermittent hemodialysis and prevention of clotting in the extracorporeal system. Nephrol Dial Transpl 2002;17(Suppl. 7): 63-71.
4. Apsner R, Buchmayer H, Lang T, et al. Simplified citrate anticoagulation for high-flux hemodialysis. Am J Kid Dis 2001;38:979-87.
5. Gabutti L, Marone C, Colucci G, Duchini F, Schönholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002;28:1419-25.
6. Janssen MJFM, Huijgens PC, Bouman AA, Oe PL, Donker AJM, van der Meulen J. Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transpl 1993;8:1228-33.
7. Kutsogiannis DJ, Mayers I, Chin WDN, Gibney RTN. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000;35:802-11.
8. Tobe SW, Aujla P, Walele AA, et al. Novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. Critical Care 2003;18:121-9.
9. Mehta RL, McDonald BR, Aguilar MM,Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990;38:976-81.
10. Evenepoel P, Maes B, Vanwalleghem J, Kuypers D, Messiaen T, Vanrenterghem Y. Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. Am J Kidney Dis 2002;39:315-23.
11. Mehta RL. Anticoagulation for continuous renal replacement therapies. In: Ronco C, Bellomo R, eds. Critical Care Nephrology. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1998;1199-211.
12. Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis 1996;27:519-24.
13. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C. The favourable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol 2004;17:819-25.
14. Cointault O, Kamar N, Bories P, et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transpl 2004;19:171-8.
15. Gupta M, Wadhwa NK, Bukovsky R. Regional citrate anticoagulation for continuous venovenous hemodiafiltration using calcium-containing dialysate. Am J Kidney Dis 2004;43:67-73.
16. Bos JC, Grooteman MPC, van Houte AJ, Schoorl M, Van Limbeek J, Nubé MJ. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transpl 1997;12:1387-93.
17. Böhler J, Schollmeyer P, Dressel B, Dobos G, Hörl WH. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996;7:234-41.
18. Schrefl A, Kellner K-H, Hartmann J, Strobl W, Falkenhagen D.A novel monitor for anticoagulation with citrate. Int J Artif Organs 2001;24:535.
19. Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G. Citrate for long-term hemodialysis: prospective study of 1009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis 2005;45:557-64.
20. Pallson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999;55:1991-7.
21. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001;60:370-4.
22. Stefanidis I, Hägel J, Maurin N. Influence of coagulation parameters on filter running time during continuous venovenous hemofiltration. Contrib Nephrol 1995;116:145-9.
23. Polanská K, Opatrný K Jr, Rokyta R, Vít L. Thrombogenicity and biocompatibility in CVVHDF with regional citrate anticoagulation. Blood Purif 2004;22:393-4.
24. Davenport A. Anticoagulation for continuous renal replacement therapy. Contrib Nephrol 2004;144:228-38.
25. Dhondt A, Vanholder R, Waterloos MA, Glorieux G, De Smet R, Lameire N. Citrate anticoagulation does not correct cuprophane bioincompatibility as evaluated by the expression of leukocyte surface molecules. Nephrol Dial Transpl 1998;13:1752-8.
26. Janssen MJ, Deegens JK, Kapinga TH, et al. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 1996;49:806-13.
27. Morgera S, Scholle C, Melzer C, et al.A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure. Nephron Clin Pract 2004;98:35-40.
28. Wada H, Sakuragawa N, Mori Y, et al. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 1999;60:273-8.
29. Watanabe R, Wada H, Watanabe Y, et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001;104:1-6.
30. Uenomachi H, Sonoda M, Miyauchi T, et al. Relationship between intracoronary thrombolysis and fibrino-coagulation. Special reference to TAT/PIC and FPA/PIC. Jpn Circ J 1996;6:149-56.
31. Scharfstein JS, Abendschein MD, Eisenberg DR, et al. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. Am J Cardiol 1996;78:503-10.
32. Culleton BF, Wilson PWF. Thrombogenic risk factors for cardiovascular disease in dialysis patients. Semin Dial 1999;12:117-25.
33. Assouad M, Eknoyan G. Does the choice of renal replacement therapy adversely affect the hypercoagulability associated with renal disease? Am J Nephrol 1998;18:175-8.
34. Hack CE, Zeerleder S. The endothelium in sepsis: source of and target for inflammation. Crit Care Med 2001;29(Suppl 7):S21-7.
35. Hakim RM. Influence of the dialysis membrane on outcome of ESRD patients. Am J Kidney Dis 1998;32(Suppl 4):71-5.
36. Wiegmann TB, McDougall ML, Diederich DA. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation: effect of membrane, bath, and citrate anticoagulation.Am J Kidney Dis 1988;11:418-24.
37. Böhler J, Donauer J, Birmelin M, Schollmeyer PJ, Hörl WH. Mediators of complement-independent granulocyte activation during haemodialysis: role of calcium, prostaglandins and leukotrienes. Nephrol Dial Transpl 1993;8:1359-65.